Letter to the Editor: statistics and clinical perception of patients' reported outcomes for palbociclib and abemaciclib: a sliding doors story.
作者信息
Gebbia Vittorio, Valerio Maria Rosaria, Martorana Federica, Sanò Maria Vita, Vigneri Paolo
机构信息
Kore University of Enna, Enna, 94100, Italy.
Medical Oncology Units, La Maddalena Clinic for Cancer, Palermo, 90100, Italy.
出版信息
J Comp Eff Res. 2023 Jun;12(6):e220212. doi: 10.57264/cer-2022-0212. Epub 2023 Apr 28.
Abstract
摘要
相似文献
1
Letter to the Editor: statistics and clinical perception of patients' reported outcomes for palbociclib and abemaciclib: a sliding doors story.
J Comp Eff Res. 2023 Jun;12(6):e220212. doi: 10.57264/cer-2022-0212. Epub 2023 Apr 28.
2
Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
Jpn J Clin Oncol. 2019 Dec 18;49(11):993-998. doi: 10.1093/jjco/hyz151.
3
Subsequent-abemaciclib Treatment After Disease Progression on Palbociclib in Patients With ER-positive HER2-negative Metastatic Breast Cancer.
Anticancer Res. 2022 Feb;42(2):1099-1106. doi: 10.21873/anticanres.15572.
4
Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials.
Breast Cancer Res Treat. 2019 Apr;174(3):597-604. doi: 10.1007/s10549-019-05133-y. Epub 2019 Jan 18.
5
Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Am J Health Syst Pharm. 2019 Aug 1;76(16):1183-1202. doi: 10.1093/ajhp/zxz121.
6
The Cyclin-Dependent Kinase 4/6 Inhibitor Abemaciclib Is Tolerated Better than Palbociclib by Advanced Breast Cancer Patients with High Serum Albumin Levels.
Biol Pharm Bull. 2022;45(10):1476-1481. doi: 10.1248/bpb.b22-00338.
7
Different inhibitors for the same target in metastatic luminal breast cancer: is there any difference?
Future Oncol. 2018 Apr;14(9):891-895. doi: 10.2217/fon-2017-0532. Epub 2018 Mar 12.
8
A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Curr Med Res Opin. 2017 Sep;33(9):1559-1569. doi: 10.1080/03007995.2017.1348344. Epub 2017 Jul 25.
9
Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer.
J Comp Eff Res. 2021 Apr;10(6):457-467. doi: 10.2217/cer-2020-0272. Epub 2021 Feb 25.
10
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Drug Metab Dispos. 2015 Sep;43(9):1360-71. doi: 10.1124/dmd.114.062745. Epub 2015 Jul 6.
本文引用的文献
1
Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review.
ESMO Open. 2022 Dec;7(6):100629. doi: 10.1016/j.esmoop.2022.100629. Epub 2022 Nov 16.
2
Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2- Metastatic Breast Cancer Treated with Abemaciclib.
Drugs Real World Outcomes. 2022 Dec;9(4):681-693. doi: 10.1007/s40801-022-00327-1. Epub 2022 Sep 12.
3
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.
Clin Cancer Res. 2022 Aug 15;28(16):3433-3442. doi: 10.1158/1078-0432.CCR-22-0305.
4
Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
Curr Med Res Opin. 2022 Aug;38(8):1319-1331. doi: 10.1080/03007995.2022.2073122. Epub 2022 May 13.
5
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
Ann Oncol. 2022 Jun;33(6):616-627. doi: 10.1016/j.annonc.2022.03.006. Epub 2022 Mar 23.
6
Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points.
J Comp Eff Res. 2022 Feb;11(2):109-120. doi: 10.2217/cer-2021-0221. Epub 2021 Nov 9.
7
Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancer.
Curr Med Res Opin. 2021 Jul;37(7):1179-1187. doi: 10.1080/03007995.2021.1923468. Epub 2021 May 20.
8
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.
J Clin Oncol. 2021 May 10;39(14):1518-1530. doi: 10.1200/JCO.20.03639. Epub 2021 Apr 1.
9
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
JAMA Oncol. 2020 Jan 1;6(1):116-124. doi: 10.1001/jamaoncol.2019.4782.
10
Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer.
J Natl Compr Canc Netw. 2019 Feb;17(2):141-147. doi: 10.6004/jnccn.2018.7094.
Zotero 插件